Catalyst Pharmaceuticals Inc (CPRX)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 387,881 | 348,548 | 375,294 | 333,661 | 300,421 | 270,041 | 241,092 | 220,221 | 206,831 | 198,661 | 188,944 | 178,651 | 169,598 | 156,628 | 111,201 | 99,676 | 87,630 | 77,983 | 63,282 | 51,176 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $387,881K
= 0.00
The debt-to-equity ratio of Catalyst Pharmaceuticals Inc has consistently been reported as 0.00, indicating that the company has no debt on its balance sheet relative to its equity. This implies that the company's operations are primarily financed by equity rather than debt. While a low or zero debt-to-equity ratio is generally viewed positively as it suggests lower financial risk and less financial leverage, it is also important to note that excessive reliance on equity financing could potentially limit the company's growth opportunities. Further analysis of Catalyst Pharmaceuticals Inc's capital structure and financial policies may provide additional insights into its strategic financial management decisions.
Peer comparison
Dec 31, 2023